Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,281 to 3,300 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: Number of Participants With Type 1 Diabetes Mellitus | 82 of 1,078 91 of 1,081 | -0.8 points -3.1 to 1.5 | 2,159 | NCT00179777 TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk |
| Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: deaths from any cause | 5 of 1,078 5 of 1,081 | 0.0 points -0.7 to 0.7 | 2,159 | NCT00179777 TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk |
| Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: serious adverse events | 379 of 1,078 377 of 1,081 | 0.3 points -3.7 to 4.3 | 2,159 | NCT00179777 TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk |
| With Complications vs Without Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications | 129 of 777 134 of 1,380 | 6.9 points 3.9 to 10.0 | 2,157 | NCT00605865 Drug Use Investigation of Jzoloft. |
| With Concomitant Drug vs Without Concomitant Drug: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug | 238 of 1,864 25 of 293 | 4.2 points 0.2 to 7.4 | 2,157 | NCT00605865 Drug Use Investigation of Jzoloft. |
| With Past Medical History of Other Illness vs Without Past Medical History of Other Illness: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness | 57 of 349 206 of 1,808 | 4.9 points 1.1 to 9.4 | 2,157 | NCT00605865 Drug Use Investigation of Jzoloft. |
| With Renal Dysfunction vs Without Renal Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction | 7 of 24 256 of 2,133 | 17.2 points 2.8 to 37.2 | 2,157 | NCT00605865 Drug Use Investigation of Jzoloft. |
| 15 Years and Higher vs Under 15 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not | 261 of 2,153 2 of 4 | -37.9 points -72.9 to -2.9 | 2,157 | NCT00605865 Drug Use Investigation of Jzoloft. |
| 120 mg Elafibranor vs Placebo: deaths from any cause | 6 of 1,437 3 of 720 | 0.0 points -0.8 to 0.6 | 2,157 | NCT02704403 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) |
| Seqirus Quadrivalent Influenza Vaccine vs Comparator Quadrivalent Influenza Vaccine: Safety Endpoint: The Frequency of Cellulitis-like Reaction. | 1 of 1,621 0 of 535 | 0.1 points -0.7 to 0.3 | 2,156 | NCT02545543 A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age |
| MVA-NP+M1 Group vs Saline Placebo Group: deaths from any cause | 0 of 1,077 1 of 1,075 | -0.1 points -0.5 to 0.3 | 2,152 | NCT03880474 Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults |
| MVA-NP+M1 Group vs Saline Placebo Group: serious adverse events | 18 of 1,077 22 of 1,075 | -0.4 points -1.6 to 0.8 | 2,152 | NCT03880474 Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults |
| Couples-based Services vs Standard of Care: deaths from any cause | 23 of 1,047 25 of 1,104 | -0.1 points -1.4 to 1.2 | 2,151 | NCT03149237 Partners-based HIV Treatment for Couples Attending Antenatal Care |
| 120 mg Elafibranor vs Placebo: serious adverse events | 190 of 1,433 95 of 717 | 0.0 points -3.1 to 3.0 | 2,150 | NCT02704403 Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) |
| Edoxaban vs Warfarin: deaths from any cause | 1 of 1,067 5 of 1,082 | -0.4 points -1.0 to 0.1 | 2,149 | NCT02072434 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) |
| Edoxaban vs Warfarin: serious adverse events | 85 of 1,067 83 of 1,082 | 0.3 points -2.0 to 2.6 | 2,149 | NCT02072434 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB) | 151 of 952 192 of 1,192 | -0.2 points -3.3 to 2.9 | 2,144 | NCT03890588 Chronic Kidney Disease Clinical Decision Support |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Decision to Not Prescribe Antibiotics for Pediatric Acute Otitis Media | 284 of 1,155 292 of 983 | -5.1 points -8.9 to -1.3 | 2,138 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| DTaP-IPV-Hep B-PRP~T vs Tritanrix-Hep B/Hib™ + OPV: serious adverse events | 91 of 1,423 46 of 710 | -0.1 points -2.4 to 2.0 | 2,133 | NCT00313911 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. |
| Group 1: DTaP-Hep B-PRP~T + OPV vs Group 2: Tritanrix-Hep B/ Hib™ + OPV: serious adverse events | 31 of 1,425 12 of 708 | 0.5 points -0.9 to 1.6 | 2,133 | NCT00348881 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants |
Code
curl "https://conductscience.org/api/comparisons/v1?page=165"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=165
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00179777-6cda80a4",
"title": "Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: Number of Participants With Type 1 Diabetes Mellitus",
"summary": "82 of 1078 against 91 of 1081; risk difference -0.8 points, 95% interval -3.1 to 1.5; NCT00179777, TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk",
"record": "/library/comparisons/NCT00179777-6cda80a4",
"nct_id": "NCT00179777",
"kind": "outcome",
"participants": 2159,
"risk_difference": {
"value": -0.008114523246015262,
"lower": -0.03119033688895616,
"upper": 0.014914713921671176
},
"group_1": "82 of 1,078",
"group_2": "91 of 1,081",
"difference": "-0.8 points",
"interval": "-3.1 to 1.5",
"trial_title": "TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk"
},
{
"id": "NCT00179777-deaths",
"title": "Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: deaths from any cause",
"summary": "5 of 1078 against 5 of 1081; risk difference 0.0 points, 95% interval -0.7 to 0.7; NCT00179777, TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk",
"record": "/library/comparisons/NCT00179777-deaths",
"nct_id": "NCT00179777",
"kind": "deaths",
"participants": 2159,
"risk_difference": {
"value": 0.00001287202291563351,
"lower": -0.006691794455961104,
"upper": 0.006730246937222214
},
"group_1": "5 of 1,078",
"group_2": "5 of 1,081",
"difference": "0.0 points",
"interval": "-0.7 to 0.7",
"trial_title": "TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=166",
"request_id": "SCyTA_CQu5XoPM76"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant